208 related articles for article (PubMed ID: 27255419)
1. CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation.
Zhang L; Zhang L; Li H; Ge C; Zhao F; Tian H; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Sci Rep; 2016 Jun; 6():27426. PubMed ID: 27255419
[TBL] [Abstract][Full Text] [Related]
2. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
[TBL] [Abstract][Full Text] [Related]
4. A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM
Karagonlar ZF; Akbari S; Karabicici M; Sahin E; Avci ST; Ersoy N; Ates KE; Balli T; Karacicek B; Kaplan KN; Celiker C; Atabey N; Erdal E
Cells; 2020 May; 9(5):. PubMed ID: 32408542
[TBL] [Abstract][Full Text] [Related]
5. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.
Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK
Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451
[TBL] [Abstract][Full Text] [Related]
6. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
7. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma.
Zhang L; Sun H; Zhao F; Lu P; Ge C; Li H; Hou H; Yan M; Chen T; Jiang G; Xie H; Cui Y; Huang X; Fan J; Yao M; Li J
Cancer Res; 2012 Aug; 72(16):4276-85. PubMed ID: 22773665
[TBL] [Abstract][Full Text] [Related]
8. CD133
Liu K; Hao M; Ouyang Y; Zheng J; Chen D
Sci Rep; 2017 Jan; 7():41499. PubMed ID: 28134312
[TBL] [Abstract][Full Text] [Related]
9. Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma.
Ding K; Liao Y; Gong D; Zhao X; Ji W
Biochem Biophys Res Commun; 2018 Jul; 502(2):194-201. PubMed ID: 29800569
[TBL] [Abstract][Full Text] [Related]
10. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
11. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation.
Hong SW; Hur W; Choi JE; Kim JH; Hwang D; Yoon SK
Oncotarget; 2016 Apr; 7(17):23482-97. PubMed ID: 26993601
[TBL] [Abstract][Full Text] [Related]
12. Oxytetracycline have the therapeutic efficiency in CD133
Song Y; Kim IK; Choi I; Kim SH; Seo HR
Sci Rep; 2018 Oct; 8(1):16100. PubMed ID: 30382122
[TBL] [Abstract][Full Text] [Related]
13. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.
Song Y; Jang J; Shin TH; Bae SM; Kim JS; Kim KM; Myung SJ; Choi EK; Seo HR
J Exp Clin Cancer Res; 2017 Mar; 36(1):38. PubMed ID: 28253902
[TBL] [Abstract][Full Text] [Related]
14. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
15. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients.
Chen YL; Lin PY; Ming YZ; Huang WC; Chen RF; Chen PM; Chu PY
BMC Cancer; 2017 Jul; 17(1):474. PubMed ID: 28687090
[TBL] [Abstract][Full Text] [Related]
16. Incomplete radiofrequency ablation promotes the development of CD133
Yuan CW; Wang ZC; Liu K; Liu DJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):416-422. PubMed ID: 30262419
[TBL] [Abstract][Full Text] [Related]
17. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
[TBL] [Abstract][Full Text] [Related]
18. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma.
Jang JW; Song Y; Kim SH; Kim JS; Kim KM; Choi EK; Kim J; Seo HR
Cancer Lett; 2017 Mar; 389():1-10. PubMed ID: 28034805
[TBL] [Abstract][Full Text] [Related]
19. Arsenite inhibits the function of CD133
Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
[TBL] [Abstract][Full Text] [Related]
20. Aquaporin 3 maintains the stemness of CD133+ hepatocellular carcinoma cells by activating STAT3.
Wang Y; Wu G; Fu X; Xu S; Wang T; Zhang Q; Yang Y
Cell Death Dis; 2019 Jun; 10(6):465. PubMed ID: 31197130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
